Harpprecht J, Hansmann M L, Westphal E, Müller-Ruchholtz W
Department of Immunology, University of Kiel, FRG.
Int Arch Allergy Appl Immunol. 1988;87(4):400-4. doi: 10.1159/000234709.
Human monoclonal antibodies may replace human or xenogeneic antisera and mouse monoclonal antibodies for therapeutic applications. The human IgM monoclonal antibody Ha6D3 was produced after in vitro immunization and fusion with a mouse myeloma. Its reactivity against human normal and leukemic cells was investigated in cytotoxicity assays, and the antigen distribution in normal tissues was investigated with biotinylated Ha6D3 and avidin-peroxidase complexes. It was shown that Ha6D3 reacts preferentially with human lymphocytic cells. Only moderate reactions with epithelial cells in some organs were observed in cryostat sections, but because of poor accessibility in vivo these reactions were considered to be negligible.
人源单克隆抗体可替代人源或异种抗血清以及鼠源单克隆抗体用于治疗应用。人IgM单克隆抗体Ha6D3是在体外免疫并与小鼠骨髓瘤细胞融合后产生的。通过细胞毒性试验研究了其对人正常细胞和白血病细胞的反应性,并使用生物素化的Ha6D3和抗生物素蛋白-过氧化物酶复合物研究了正常组织中的抗原分布。结果表明,Ha6D3优先与人淋巴细胞发生反应。在低温切片中仅观察到与某些器官上皮细胞的中等反应,但由于体内可达性差,这些反应被认为可忽略不计。